ANDA Submission Process

Getting an Abbreviated New Drug Application right from the start is one of the most important things a generic drug company can do. The FDA has stringent requirements for ANDA filing, and a Refusal to Receive (RTR) does not just delay your approval. It costs you 25% of the application fee and requires a full resubmission. For Paragraph IV applications, an RTR can also mean losing 180-day market exclusivity, which can have significant commercial consequences.

The process starts earlier than most companies expect

Successful ANDA filing begins at the product development stage, not at submission. Before you file, your formulation needs to meet FDA requirements including inactive ingredient guidance (IIG), Q1 and Q2 composition standards, appropriate API particle size, and correct reference listed drug (RLD) or reference standard (RS) identification. Mistakes at this stage are costly and difficult to correct later. Where there is any uncertainty, obtaining FDA clarification early through the controlled correspondence process is strongly recommended.

API source selection matters

Choosing the right drug substance source is a critical and often underestimated step. Before committing to an API supplier, confirm that the DMF holder appears on the FDA's publicly available list of DMFs available for reference, and that the DMF holder is current on their GDUFA facility fee obligations. An API source that is not in good standing with the FDA can derail your entire submission.

Contract facilities and testing labs

All contract testing laboratories and outsourced manufacturing facilities referenced in your ANDA must be in FDA compliance. A compliance issue at a contract facility, even one you do not control, can delay your approval significantly. Identifying and vetting these partners early in the process is essential.

Foreign companies: US Agent requirement

Foreign ANDA applicants are required to designate a US FDA Agent. The FDA communicates with foreign companies through their US Agent, and slow or missed communications can directly impact your approval timeline. Choosing a responsive, experienced US Agent is not a formality. It is a practical necessity.

How FDABasics can help

ANDA approval is a complex, high-stakes process that rewards careful preparation and penalizes shortcuts. FDABasics provides end-to-end ANDA support including technical gap analysis, controlled correspondence, pre-submission meetings, labeling review, eCTD preparation and submission, cGMP audit support, and citizen petition filing. We draw on deep experience with the ANDA process to help you submit with confidence and avoid the delays that come from getting the details wrong.